It is well known that the reported EGFR mutation rates in patients with lung adenocarcinoma vary widely among different populations worldwide (ranging from 10–20% in European and North American cohorts [20–23] to more than 50% in Asian populations [24,25]), and that EGFR mutation status is significantly associated with female gender and never smoking status [20–25]. The gene discussed is EGFR; the disease is lung adenocarcinoma.